Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Hironori OchiMasayuki KurosakiKouji JokoToshie MashibaNobuharu TamakiKaoru TsuchiyaHiroyuki MarusawaToshifumi TadaShinichiro NakamuraRyoichi NaritaYasushi UchidaTakehiro AkahaneMasahiko KondoNami MoriShintaro TakakiKeiji TsujiAtsunori KusakabeKoichiro FurutaHaruhiko KobashiHirotaka AraiMichiko NonogiTakashi TamadaChitomi HasebeNamiki IzumiPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)
Pretreatment NLR is a simple tool for routine measurement in clinical practice. It can predict PFS in patients with unresectable HCC treated with atezolizumab plus bevacizumab, especially mALBI grade 1 or 2a.